Clinical practice guidelines: time to move the debate from the how to the who.
Van der Weyden
Martin B
MB
D016265:Conflict of Interest; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use; D004345:Drug Industry; D019317:Evidence-Based Medicine; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors; D008565:Membrane Proteins; D017410:Practice Guidelines as Topic / Q000592:standards*; D011451:Prostaglandin-Endoperoxide Synthases
D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D008565:Membrane Proteins; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases